Drug intelligence / Profile preview

BL-M24D1

Development stage: Phase 1
Lead developer: Biokin Pharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**BL-M24D1** is an investigational antibody-drug conjugate (ADC) developed by Sichuan Baili Pharmaceutical, a subsidiary of Sichuan Biokin Pharma, targeting various advanced solid tumors and hematologic malignancies. It incorporates next-generation toxins derived from the same small molecule platform and is administered via intravenous infusion in 2-week cycles. Currently in Phase I clinical trials evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy across multiple indications, including non-small cell lung cancer, gastrointestinal tumors, head and neck squamous cell carcinoma, multiple myeloma, and other relapsed/refractory malignancies.[5][6][7][9]

Beyond the preview

Go deeper on BL-M24D1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BL-M24D1.

Explore the full profile